Company news

Clene Inc. news in 2023

Clene Inc.'s news releases, calls and decks from 2023, newest first.

View company

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

December 20, 2023

Clene Provides Update on ALS Clinical Development Meeting With FDA

December 20, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

December 13, 2023

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

November 6, 2023

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

October 4, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

September 27, 2023

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

September 24, 2023

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

September 24, 2023

Clene to Present at Upcoming September Conferences

August 29, 2023

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

August 28, 2023

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

August 13, 2023

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

June 25, 2023

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

June 20, 2023

Clene Announces Pricing of $40 Million Public Offering

June 15, 2023

Clene to Participate in the Maxim Group Virtual Healthcare Conference

June 14, 2023

Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

June 14, 2023

Clene Announces Launch of Proposed Public Offering

June 14, 2023

Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis

May 24, 2023

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

May 11, 2023

ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

April 24, 2023

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

April 10, 2023

Clene Appoints Neurology Expert to Executive Team

March 15, 2023

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

March 12, 2023

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

March 8, 2023

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

March 7, 2023

Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

March 6, 2023

New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial

March 5, 2023

Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System

February 26, 2023

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

February 12, 2023

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

January 10, 2023

Decks in 2023